DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Tabrecta is a drug marketed by Novartis Pharm and is included in one NDA. There are five patents protecting this drug.
This drug has one hundred and forty-one patent family members in forty countries.
The generic ingredient in TABRECTA is capmatinib hydrochloride. One supplier is listed for this compound. Additional details are available on the capmatinib hydrochloride profile page.
Tabrecta will be eligible for patent challenges on May 6, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 22, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TABRECTA
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||69|
|Drug Prices:||Drug price information for TABRECTA|
|What excipients (inactive ingredients) are in TABRECTA?||TABRECTA excipients list|
|DailyMed Link:||TABRECTA at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for TABRECTA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for TABRECTA
|Country||Patent Number||Estimated Expiration|
|Canada||2724742||Get Started Free|
|Brazil||112017000953||Get Started Free|
|Mexico||368802||Get Started Free|
|Japan||2015145378||Get Started Free|
|Brazil||PI0912882||Get Started Free|
|South Korea||101706784||Get Started Free|
|Eurasian Patent Organization||201691862||Get Started Free|
|>Country||>Patent Number||>Estimated Expiration|